DiGiovanna MP - Search Results

1

Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition.

Gale M, Li Y, Cao J, Liu ZZ, Holmbeck MA, Zhang M, Lang SM, Wu L, Do Carmo M, Gupta S, Aoshima K, DiGiovanna MP, Stern DF, Rimm DL, Shadel GS, Chen X, Yan Q. Gale M, et al. Among authors: digiovanna mp. Cancer Res. 2020 Feb 1;80(3):524-535. doi: 10.1158/0008-5472.CAN-18-3985. Epub 2019 Nov 5. Cancer Res. 2020. PMID: 31690671 Free PMC article.

2

Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor.

DiGiovanna MP, Stern DF. DiGiovanna MP, et al. Cancer Res. 1995 May 1;55(9):1946-55. Cancer Res. 1995. PMID: 7728765

3

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.

DiGiovanna MP, Carter D, Flynn SD, Stern DF. DiGiovanna MP, et al. Br J Cancer. 1996 Sep;74(5):802-6. doi: 10.1038/bjc.1996.439. Br J Cancer. 1996. PMID: 8795585 Free PMC article.

4

Active signaling by Neu in transgenic mice.

DiGiovanna MP, Lerman MA, Coffey RJ, Muller WJ, Cardiff RD, Stern DF. DiGiovanna MP, et al. Oncogene. 1998 Oct 8;17(14):1877-84. doi: 10.1038/sj.onc.1202091. Oncogene. 1998. PMID: 9778054

5

Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.

Thor AD, Liu S, Edgerton S, Moore D 2nd, Kasowitz KM, Benz CC, Stern DF, DiGiovanna MP. Thor AD, et al. Among authors: digiovanna mp. J Clin Oncol. 2000 Sep 15;18(18):3230-9. doi: 10.1200/JCO.2000.18.18.3230. J Clin Oncol. 2000. PMID: 10986055

6

Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors.

Claus EB, Chu P, Howe CL, Davison TL, Stern DF, Carter D, DiGiovanna MP. Claus EB, et al. Among authors: digiovanna mp. Exp Mol Pathol. 2001 Jun;70(3):303-16. doi: 10.1006/exmp.2001.2366. Exp Mol Pathol. 2001. PMID: 11418009

7

Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates.

DiGiovanna MP, Chu P, Davison TL, Howe CL, Carter D, Claus EB, Stern DF. DiGiovanna MP, et al. Cancer Res. 2002 Nov 15;62(22):6667-73. Cancer Res. 2002. PMID: 12438265

8

Synergistic interactions between tamoxifen and trastuzumab (Herceptin).

Argiris A, Wang CX, Whalen SG, DiGiovanna MP. Argiris A, et al. Among authors: digiovanna mp. Clin Cancer Res. 2004 Feb 15;10(4):1409-20. doi: 10.1158/1078-0432.ccr-1060-02. Clin Cancer Res. 2004. PMID: 14977844

9

Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.

DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D 2nd, Thor AD. DiGiovanna MP, et al. J Clin Oncol. 2005 Feb 20;23(6):1152-60. doi: 10.1200/JCO.2005.09.055. J Clin Oncol. 2005. PMID: 15718311

10

In vitro and in vivo effects of combination of Trastuzumab (Herceptin) and Tamoxifen in breast cancer.

Wang CX, Koay DC, Edwards A, Lu Z, Mor G, Ocal IT, Digiovanna MP. Wang CX, et al. Among authors: digiovanna mp. Breast Cancer Res Treat. 2005 Aug;92(3):251-63. doi: 10.1007/s10549-005-3375-z. Breast Cancer Res Treat. 2005. PMID: 16155796

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters